These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14709961)

  • 1. Reply to article by Margolese and associates on tolerance and rebound during maintenance with quetiapine.
    Goldstein J; Macfadden W
    J Clin Psychopharmacol; 2004 Feb; 24(1):102-3; author reply 103-4. PubMed ID: 14709961
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
    Fernandez HH; Trieschmann ME; Okun MS
    Mov Disord; 2005 Jan; 20(1):104-5. PubMed ID: 15390047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia.
    Onor ML; Saina M; Aguglia E
    Am J Alzheimers Dis Other Demen; 2006 Dec-2007 Jan; 21(6):448-53. PubMed ID: 17267378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine in the treatment of psychotic adolescents: a case series of 23 patients with severe early onset psychosis.
    Beer F; Heinrich H; Springer S; Rüth U; Freisleder FJ
    World J Biol Psychiatry; 2007; 8(1):38-41. PubMed ID: 17366348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate.
    Adetunji B; Basil B; Mathews M; Williams A; Osinowo T
    J Clin Psychiatry; 2006 Mar; 67(3):497; author reply 497-8. PubMed ID: 16649843
    [No Abstract]   [Full Text] [Related]  

  • 6. Quetiapine: efficacy, tolerability and safety in schizophrenia.
    Miodownik C; Lerner V
    Expert Rev Neurother; 2006 Jul; 6(7):983-92. PubMed ID: 16831113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome with use of quetiapine in mental retardation.
    Dan A; Bharadwaj R; Grover S
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):255-6. PubMed ID: 19335404
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia.
    Donahue CB; Kushner MG; Thuras PD; Murphy TG; Van Demark JB; Adson DE
    J Anxiety Disord; 2009 Apr; 23(3):362-8. PubMed ID: 19157776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine treatment in early psychosis: no evidence of cataracts.
    Whitehorn D; Gallant J; Woodley H; Rui Q; Milliken H; Kopala L
    Schizophr Res; 2004 Dec; 71(2-3):511-2. PubMed ID: 15474924
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of quetiapine on auditory P300 response in patients with schizoaffective disorder: preliminary study.
    Korostenskaja M; Dapsys K; Siurkute A; Dudlauskaite A; Pragaraviciene A; Maciulis V; Kähkönen S
    Ann Clin Psychiatry; 2009; 21(1):49-50. PubMed ID: 19239832
    [No Abstract]   [Full Text] [Related]  

  • 11. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D; Barak Y; Mirecky I; Mazeh D
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment guidelines for non-schizophrenic psychotic disorders?].
    Jäger M; Frasch K; Weinmann S; Becker T
    Psychiatr Prax; 2007 Nov; 34(8):370-6. PubMed ID: 17806003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quetiapine for the treatment of cocaine dependence: an open-label trial.
    Kennedy A; Wood AE; Saxon AJ; Malte C; Harvey M; Jurik J; Kilzieh N; Lofgreen C; Tapp A
    J Clin Psychopharmacol; 2008 Apr; 28(2):221-4. PubMed ID: 18344735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine as a first-choice agent in subjects at high-risk to psychosis?
    O'Connor R; Sota M; Cortesi M; Fusar-Poli P
    Med Hypotheses; 2007; 69(1):230. PubMed ID: 17258403
    [No Abstract]   [Full Text] [Related]  

  • 16. Quetiapine vs. risperidone in treating psychosis in neurosyphilis: a case report.
    Taycan O; Ugur M; Ozmen M
    Gen Hosp Psychiatry; 2006; 28(4):359-61. PubMed ID: 16814638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Young people at ultra high risk for psychosis: a research update.
    Yung AR; Nelson B
    Early Interv Psychiatry; 2011 Feb; 5 Suppl 1():52-7. PubMed ID: 21208392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quetiapine blood level variability.
    Savasi I; Millson RC; Owen JA
    Can J Psychiatry; 2002 Feb; 47(1):94. PubMed ID: 11873715
    [No Abstract]   [Full Text] [Related]  

  • 19. Quetiapine as treatment for delirium during weaning from ventilation: a case report.
    Seemüller F; Volkmer E; Vogel T; Hummel T; Krauseneck T; Riedel M; Padberg F
    J Clin Psychopharmacol; 2007 Oct; 27(5):526-8. PubMed ID: 17873696
    [No Abstract]   [Full Text] [Related]  

  • 20. Should attenuated psychosis syndrome be included in DSM-5?
    Fusar-Poli P; Yung AR
    Lancet; 2012 Feb; 379(9816):591-2. PubMed ID: 22340290
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.